The following is a list of listed companies in Jiangsu Free Trade Zone, the most valuable stocks in Jiangsu Free Trade Zone:
Feilida (300240):20 1435 net profit14.35 million yuan, down 80% year-on-year.
Feilida (300240) disclosed its performance report on the evening of February 2 1 8. In 20 18, the company realized a total operating income of 365,438+99 million yuan, up 4.37% year-on-year. The net profit was 6.5438+0.43488 million yuan, down 79.97% year-on-year. The basic earnings per share is 0.04 yuan. Affected by the downward pressure of the economic situation, the profits of branches in some regions dropped sharply compared with the same period of last year; Some of the company's new projects are in the investment period, which has a certain impact on the company's operating performance.
Suzhou Hi-Tech (600736): The living room of Huada Life and Health Town has been completed and put into use.
Suzhou Hi-Tech (600736) replied to investors on the interactive platform on April 1 day that the living room of Huada Life and Health Town has been completed and construction has begun, and the first and second phases of the town industrial park are also under construction. Note: From 2065438 to September 2007, Suzhou Hi-tech Zone Management Committee, Huada Gene, Vanke and Suzhou Hi-tech signed the Framework Agreement on Huada Life and Health Town, aiming to build a "Huada Life and Health Town" covering health technology, health services and precision medical care.
The acquisition of Frantec (603966) can be successfully completed and the coordinated development is expected.
Event: The company announced on 65438+February 10 that the acquisition of shares in RVH and RVB has been completed. From the delivery date, Frenta Austria Holding Company directly holds 0/00% equity of RVH and RVB/KLOC, and finally holds 0/00% equity of Voith Drive/KLOC.
The acquisition has been successfully completed, and the coordinated development is expected: Voith Drive, as a market leader in the special crane and material handling industry, has advanced technology, professional service, excellent brand and strong profitability. This acquisition will enable the company to acquire a long-standing high value-added brand, leading mature technology and experienced management team, enhance its competitiveness in the middle and high-end crane and material handling industries, and improve its profitability, in line with the company's international development strategy; It also helps the company to further expand overseas markets and enhance brand influence. This acquisition has a positive impact on the company's future business development and profitability, which is conducive to the company's long-term development.
Aoyang Shunchang (002245) subsidiary plans to cooperate strategically with Jiangsu Dayi in ternary cylindrical lithium battery business.
Aoyang Shunchang (002245. SZ) announced that Jiangsu Tian Peng Power Supply Co., Ltd. (hereinafter referred to as "Tian Peng Power Supply" or "Party B"), a holding subsidiary of the company, and Jiangsu Dayi Electromechanical Tools Co., Ltd. (hereinafter referred to as "Jiangsu Dayi" or "Party A") signed a strategic purchase on April 3, 2022.
It is reported that Party A plans to purchase10.50 billion ternary cylindrical lithium batteries of various shapes from Party B in 2022, 2020 and 20021year. The specific quantity is subject to the actual order.
Jiangsu Tian Peng Power Supply Co., Ltd. is the core enterprise of the company's ternary power lithium battery business. After 10 years of development, it has become the leader of domestic tool lithium-ion batteries. Jiangsu Dayi, as a professional power tool manufacturer in China, has a strong brand influence in the domestic power tool market.
Bonded Science and Technology (600794): It is estimated that the net profit of 20 18 will turn losses into profits.
After the close of1October 29th, Bonded Science and Technology (600794) released the 20 18 annual performance forecast. During the reporting period, the company expects to realize a net profit attributable to shareholders of listed companies of about 35 million yuan, thus turning losses into profits. According to the company, during the reporting period, yangtze river international Port Co., Ltd., a subsidiary of Zhangjiagang Free Trade Zone, achieved a net profit of about 39 million yuan, an increase of about 27 million yuan compared with the same period of last year, mainly due to the increase in the total amount of goods and inventory received by yangtze river international, the increase in operating income and the overall decrease in costs and expenses.
Nanjing Panda (600775): It is estimated that the net profit of 20 18 will increase by 50% to 70% year-on-year.
654381On the afternoon of October 23rd, Nanjing Panda (600775) released the 20 18 annual performance forecast. During the reporting period, the estimated net profit attributable to shareholders of listed companies is 1.6 1 100 million yuan to183 million yuan, up 50% to 70% year-on-year. The company said that in 20 18, the company strengthened business integration and optimized resource allocation. Intelligent transportation, intelligent building and other products are in line with the development trend of the industry, with increased orders and enhanced profitability.
The net profit of Nanjing Port (002040)20 18 is expected to increase by 30%-80%.
Nanjing Port disclosed the third quarterly report of 20 18. In the first three quarters of 20 18, the company realized operating income of 519,051462.38 yuan, up by 7.73% year-on-year; The net profit attributable to shareholders of listed companies was129,313,492.94 yuan, a year-on-year increase of 73.86%. The company predicts that the net profit attributable to shareholders of listed companies in 20 18 will be138.23 million yuan to191390,000 yuan, with a year-on-year increase of 30.00% to 80.00%.
Financial expenses and non-recurring gains and losses drag down performance. The net profit of Lianyungang (601008) in 2018 was reduced by 72% in advance.
A few days ago, Lianyungang announced the 20 18 annual performance forecast. According to the report, it is estimated that the company's net profit attributable to shareholders of listed companies will decrease by 8,654.38+0.9 million yuan compared with the same period of last year, a year-on-year decrease of about 72%; After deducting non-recurring gains and losses, compared with the previous year (restated adjustment data), the company's net profit attributable to shareholders of listed companies is expected to decrease by RMB222,654,380+000, a year-on-year decrease of about 65,438+0.04%.
The reporter learned that Lianyungang, founded in 200 1, is the ninth largest port in China, and ranks as the main hub port in the Yangtze River Delta port group along with Ningbo Port and Shanghai Port. The company's main business is port cargo handling, warehousing and related port management services, of which port cargo handling and warehousing services account for more than 80% of the company's total business. The main types of goods are iron ore, coal, nonferrous metal ore, laterite nickel ore, steel, plywood, machinery and equipment, grain, alumina, coke and so on.
Essence pharmaceutical (002349): In 20 1 8, the sales revenue of single variety of snake slices of Wang Baochi and Ji Desheng broke through1100 million for the first time.
The online presentation meeting of essence pharmaceutical's (002349)20 18 annual performance was held in Panorama.com on Thursday afternoon. As for the sales of traditional Chinese medicine preparations, which account for the highest proportion of the company's revenue, Zhong, the general manager of the company, said that the sales revenue of the company's proprietary Chinese medicines increased by more than 20% in 20 18, among which the sales revenue of Wang Baochi and Ji Desheng snake tablets exceeded 1 100 million yuan for the first time.
Essence pharmaceutical's 20 18 annual report shows that the company achieved operating income of 1 354,705,881.53 yuan in 20 18, with a year-on-year increase of 20.86%. The net profit attributable to shareholders of listed companies was 229,665,275.60 yuan, up 365,438+0.00% year-on-year, and the basic earnings per share was 0.2756 yuan. Based on 8 14 and180,908, a cash dividend of 0.50 yuan (including tax) is distributed to all shareholders for every 10 share.
Traditional Chinese medicine preparation is the product with the highest income in essence pharmaceutical. In 20 18, the revenue reached 409 million yuan, accounting for 30.2% of the revenue, slightly higher than that in 20 17, and its gross profit margin reached 73.75%.
Essence pharmaceutical is mainly engaged in the research, development, production and sales of Chinese patent medicines, APIs, pharmaceutical intermediates and western medicine preparations.